“Durability of Response in Patients With Chronic Plaque Psoriasis Treated With Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S87, https://doi.org/10.25251/skin.2.supp.88.